Abstract: Provided herein are, inter alia, methods useful for delivering nucleic acids and kinase inhibitors to a cell. The methods provided herein include the delivery of therapeutic nucleic acids to cancer cells by contacting a cancer cell with a kinase inhibitor and a therapeutic nucleic acid. The methods provided herein are therefore, inter alia, useful for the treatment of cancer.

Abstract: An orthopaedic joint prosthesis assembly includes a head part of an orthopaedic joint prosthesis component and an alignment guide. The head part has a spherical bearing surface for articulation with a corresponding joint surface, and an assembly surface having a first bore formed in it for receiving a spigot on another part of the orthopaedic joint prosthesis. The bore has a first axis that extends perpendicular to the assembly surface. There is a discontinuity at an interface between the bearing surface and the assembly surface, and the assembly surface is arranged on a plane which is parallel to, or contains, a plane which is defined by the opening to the bore in the head part when the head part is viewed from one side in cross-section. The alignment guide has an axial portion and an arm extending from the axial portion.

Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.

Abstract: According to some embodiments, methods for covalently or non-covalently conjugating an antibody (e.g., hu3S193 or other humanized antibody) or functional fragment thereof with an siRNA molecule (e.g., anti-STAT3 siRNA) is provided. Such methods may include (1) modifying an antibody or functional fragment thereof with a linker to provide a linker-modified antibody, combining a target siRNA with a disulfide containing aldehyde linker to provide a linker-modified target siRNA and combining the linker-modified target siRNA with linker-modified antibody to form an antibody-siRNA complex; or (2) modifying an antibody or functional fragment thereof with a (Arginine)9 peptide to form an antibody-9R complex and associating an siRNA molecule with the antibody-9R complex to form an electrostatic antibody-9R:siRNA complex. In another embodiment, an antibody-siRNA conjugate may be used in methods for suppressing or silencing STAT3 protein expression in a cancer cell.